ZIA BC 010763 (ZIA) | |||
---|---|---|---|
Title | Building on the success of the adoptive immunotherapy of cancer | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | Restifo, Nicholas | NCI Program Director | N/A |
Cancer Activity | N/A | Division | CCR |
Funded Amount | $1,097,105 | Project Dates | 10/01/2005 - 00/00/0000 |
Fiscal Year | 2014 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Autoimmune Diseases (10.0%) Cancer (100.0%) Digestive Diseases (10.0%) Surgery (20.0%) |
Brain (10.0%) Breast (5.0%) Colon/Rectum (5.0%) Hodgkins disease (5.0%) Kidney Cancer (10.0%) Kidney Disease (10.0%) Lung (5.0%) Melanoma (30.0%) Nervous System (10.0%) Non Hodgkins Lymphoma (5.0%) Ovarian Cancer (10.0%) Pancreas (5.0%) Prostate (10.0%) Urinary System (10.0%) |
||
Research Type | |||
Systemic Therapies - Clinical Applications Application of Model Systems |
|||
Abstract | |||
Adoptive immunotherapy for cancer: building on success Substantial progress has been made in our understanding of the molecular and cellular bases of T cell mediated anti-tumor responses. T cells are potent effectors of the adaptive anti-tumor immune response. Some target antigens recognized by tumor-reactive CD8+ T cells are non-mutated self-antigens that are also expressed by tumor cells. The molecular signals that modulate T cell activation, function and memory are being elucidated. Both positive and negative signals from co-stimulatory molecules have been shown to shape the anti-tumor response. Cytokines, including those with receptors that contain the common cytokine-receptor gamma chain have been shown to alter the programming of effector CD8+ T cells." |